Bergh T, Nillius S J, Enoksson P, Larsson S G, Wide L
Clin Endocrinol (Oxf). 1982 Dec;17(6):625-31. doi: 10.1111/j.1365-2265.1982.tb01636.x.
Fourteen women with large prolactinomas experienced a total of nineteen bromocriptine-induced term pregnancies. None of the women had received prior pituitary tumour therapy. Post-partum sellar X-ray examinations showed signs of tumour enlargement in two women. Only one of them had clinical symptoms of tumour expansion with visual field defects during the pregnancy. The visual impairment improved when bromocriptine treatment was reinstituted and the pregnancy continued to term. The other twelve women had a total of seventeen uneventful pregnancies without symptoms or signs of pituitary tumour expansion. Thus, medical therapy with dopamine receptor agonists is the primary treatment for most infertile women with prolactinomas. The risk of serious pregnancy-induced tumour expansion is very small in properly investigated and carefully supervised patients with large PRL-secreting pituitary adenomas.
14名患有大泌乳素瘤的女性共经历了19次溴隐亭诱导的足月妊娠。这些女性均未接受过垂体肿瘤治疗。产后蝶鞍X线检查显示,两名女性有肿瘤增大迹象。其中只有一名女性在孕期出现肿瘤扩展的临床症状并伴有视野缺损。重新开始溴隐亭治疗并继续妊娠至足月后,视力障碍有所改善。另外12名女性共经历了17次平安无事的妊娠,没有垂体肿瘤扩展的症状或体征。因此,对于大多数患有泌乳素瘤的不孕女性,多巴胺受体激动剂药物治疗是主要治疗方法。在经过适当检查和仔细监测的大泌乳素分泌型垂体腺瘤患者中,严重的妊娠诱导肿瘤扩展风险非常小。